Conference Coverage
Latest Content
May 22, 2026 | News
FNI Outperforms FIB-4 in Predicting 20-Year MASLD Mortality in T2D
Health Equity & Access Weekly Roundup: May 22, 2026
May 22, 2026
A Structured Training Framework Aims to Standardize Brachytherapy Practice in Soft Tissue Sarcoma
May 22, 2026
AYA ALL Care Evolves Beyond Chemotherapy as Survival Gaps Persist
May 22, 2026
Expanding ILD Care Access Through Shared Models and Telehealth: Yet Khor, MD, PhD
May 22, 2026
Advertisement
Shorts
0:42
Stop Using 'One Size Fits All' for Pneumonia: Janet Lee, MD
21 hours ago
by
Sabrina McCrear(+1 more)
0:42
Sparsentan Approval Marks Historic Step Forward for Patients With FSGS: Kirk Campbell, MD
2 days ago
by
Brooke McCormick(+1 more)
0:54
Advocacy Is Not a Solo Endeavor: Rose Gerber, MS
4 days ago
by
Maggie L. Shaw(+1 more)
1:26
Ensuring Treatment Access Remains Central Challenge in Lung Cancer Care: Deborah Doroshow, MD, PhD
9 days ago
by
Brooke McCormick(+2 more)
0:44
Why Local Cancer Care Is in Crisis: Kathy Oubre, MS
10 days ago
by
Maggie L. Shaw(+1 more)
2:17
History of Medicine Offers Lessons for Modern Cancer Care: Deborah Doroshow, MD, PhD
12 days ago
by
Brooke McCormick(+2 more)
2:28
AJMC Research Roundup: April 2026
15 days ago
by
Christina Mattina
2:13
Study Finds Minimal Shifts in Primary Care Selection Following Benefit Design Changes: Tim McDonald, PhD, MPP
15 days ago
by
Brooke McCormick(+1 more)
1:33
Consumer Inertia, Information Gaps Contribute to Inefficiency in Health Care Markets: Bryan E. Dowd, PhD
16 days ago
by
Brooke McCormick(+1 more)
0:40
Efgartigimod Will Likely Be Used as Second-Line Treatment for oMG: Carolina Barnett-Tapia, MD, PhD
16 days ago
by
Julia Bonavitacola(+1 more)
A Conference You Don't Want To Miss
Two days of strategy, insights, and innovation in patient-centered oncology care. September 24–25.
Innovation Starts Here
We’re now accepting applications for OncoVenture—submit your oncology innovation.
Center on Health Equity & Access
Start seeing what truly shapes access and learn how you can redefine the landscape.
Stay Ahead of Clinical and Policy Change
AJMC's e-newsletter features payer-focused insights across priority disease areas.
Podcasts
Center on Health Equity & Access
Advertisement
All News
Advertisement
Endometriosis is often mistaken for IBS, fibroids, UTIs, PID, and ovarian cysts, potentially delaying diagnosis, treatment, and fertility care for years.
The FDA approves Datroway for first-line metastatic triple-negative breast cancer in immunotherapy-ineligible patients.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
This review will appear in the June issue of Evidence-Based Oncology.
Three hospital systems claim CVS Health secretly pocketed 340B savings meant for indigent care.
A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.
Eli Lilly's triple agonist achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, matching bariatric surgery levels.
New scientific statement argues that heart failure with mildly reduced ejection fraction should no longer be treated as a “gray zone.”
The Trump administration fired USPSTF leaders, sparking concerns over the future of ACA-mandated free medical screenings and preventive care.
Advertisement
Advertisement
Trending on AJMC
1
CVS Health Sued Over Alleged Scheme to Siphon 340B Drug Program Savings
2
Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer
3
Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial
4
FNI Outperforms FIB-4 in Predicting 20-Year MASLD Mortality in T2D
5